Search

NEUWERK advises ITM on license arrangement with French Cancer Specialist AAA

Hamburg - NEUWERK has advised ITM Isotope Technologies Munich, a German-based specialised radiopharmaceutical company, on a long-term license and supply agreement with Novartis subsidiary and French cancer specialist Advanced Accelerator Applications (AAA).


Under the agreement, ITM will provide AAA with supply of highly pure no-carrier-added (n.c.a.) Lutetium-177 for its investigational 177Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer. Pending approval of investigational drug candidate 177Lu-PSMA-617, ITM would continue to provide its proprietary n.c.a. 177Lu during the commercial phase, supporting the scalability and security-of-supply for patients world-wide. In addition, the parties have agreed that n.c.a. 177Lu supplied by ITM will be used in future pipeline investigations.


NEUWERK advised ITM on the transaction.


For more information, please see ITM's press release.



Advisors for ITM Isotope Technologies Munich:

NEUWERK, Hamburg

Börge Seeger, MLE, JSM, CLP (transaction lead, partner)

Dr. Jonas Welge (Associate)



About ITM Isotope Technology Munich:

ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class mecial radioisotopes and generator platforms for a new generation of targeted cancer diagnostics and therapies.


About NEUWERK:

NEUWERK was founded in 2016 by lawyers from Freshfields Bruckhaus Deringer and ROXIN in Hamburg. NEUWERK brings together specialists from the fields of labor law, corporate law/M&A, IP/IT, real estate law, litigation and white-collar criminal law/criminal compliance.


Press contact: For further questions please contact Dr. Sebastian Naber (sebastian.naber@neuwerk.legal), T +49 40 340 5757-30.



NEUWERK Rechtsanwälte PartG mbB, Gänsemarkt 35, 20354 Hamburg, Germany www.neuwerk.legal